Leerink raises Beam Therapeutics price target on AATD data
ArchivedSingle Source|2 articles|1 sources|1 blocks
Detected: Updated: Analyzed:
NarrativeRadar Analysis·Reviewed by M. Reyes·AI-assisted, editorially supervised·Based on 2 articles from 1 sources
Leerink has increased its stock price target for Beam Therapeutics following new data from trials on Alpha-1 Antitrypsin Deficiency (AATD). William Blair also maintained a positive rating on Beam Therapeutics based on the encouraging trial results. These developments may influence investor confidence and affect Beam Therapeutics' market valuation.
Reported Facts
Observable data points shared across all narratives
- •Leerink raised the stock price target for Beam Therapeutics on March 25, 2026.
- •The price target increase was based on new data related to Alpha-1 Antitrypsin Deficiency (AATD) trials.
- •William Blair reiterated a positive stock rating for Beam Therapeutics on the same day.
- •The trial data showed promising results that support Beam Therapeutics' development efforts.
What Could Happen If...
- ▸Beam Therapeutics advances further positive clinical trial results for AATD Investor confidence could increase, potentially driving up the company's stock price and enabling more funding for research.
Market Exposure
StocksBeam TherapeuticsUpward Pressure
Positive AATD trial data and raised price targets by analysts could boost investor demand for Beam Therapeutics shares.
This is not investment advice. Market exposure is based on conditional event analysis.
Source Coverage
FINANCE
2 articles
Signals
Single-block coverage
Related Events
▸Leerink Maintains Arrowhead Pharma Stock Rating After Partner DataArchived▸William Blair maintains AbbVie rating after obesity drug dataArchived▸H.C. Wainwright lowers Karyopharm price target after trial resultsArchived▸Truist Maintains Buy on AbCellera Ahead of Key 2H26 DataArchived▸Truist Maintains Ascentage Pharma Rating Amid Pipeline Advances